Last reviewed · How we verify
NuvaRing Vaginal Ring
At a glance
| Generic name | NuvaRing Vaginal Ring |
|---|---|
| Also known as | NuvaRing |
| Sponsor | Lupin Research Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS (PHASE4)
- Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity (PHASE4)
- Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring (PHASE1)
- A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450) (PHASE3)
- A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012) (PHASE2)
- Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733) (PHASE4)
- Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063) (PHASE3)
- An Open-label, Randomized, 2-Period, Crossover, Pharmacokinetics Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NuvaRing Vaginal Ring CI brief — competitive landscape report
- NuvaRing Vaginal Ring updates RSS · CI watch RSS
- Lupin Research Inc portfolio CI